THIRTY MADISON BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Thirty Madison's BCG Matrix preview highlights where its core offerings-hair loss treatment, telehealth services, and chronic care initiatives-sit in the competitive landscape, hinting at which are scaling fast versus which may need reallocation. The full BCG Matrix delivers quadrant-by-quadrant data, strategic recommendations, and actionable insights to prioritize capital and product focus. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary to present, plan, and act with confidence.
Stars
Nurx Reproductive Health 40 Percent Market Share
Thirty Madison's Nurx integration captures ~40% of the U.S. digital reproductive-health market, driving $220M in 2025 revenue from birth control and PrEP-a high-growth segment as telehealth uptake rose to 38% of adults by 2025.
Strong unit economics (CAC ~$90, LTV ~$540) justify continued marketing spend to defend share versus Hims & Hers, though marketing costs consumed ~28% of segment revenue in 2025.
High user volume-~1.2M annual patients-makes Nurx the portfolio's crown jewel, delivering scale and cross-sell potential across Thirty Madison's specialty-care brands.
GLP-1 Weight Management Program 150 Percent Growth
By end-2025 Thirty Madison's GLP-1 weight management program drove 150% revenue growth, making metabolic health its primary growth engine with estimated GLP-1 sales of $120 million and representing ~40% of total revenue.
Rapid market expansion-global obesity drug sales projected >$150B in 2025-helped Thirty Madison capture a growing slice, supported by 200% rise in patient enrollments year-over-year.
High demand forces heavy capex: $25M in 2025 supply-chain and $12M in clinical oversight spend, keeping the program a Star in the BCG matrix due to high growth and significant market share gains.
Thirty Madison Enterprise B2B Solutions
Thirty Madison Enterprise B2B Solutions shifted from DTC to employer-sponsored care, unlocking corporate budgets after securing contracts with 48 Fortune 500 firms by FY2025 and driving segment revenue to $142 million in 2025.
The unit sells migraine and reproductive-health benefit packages, a market posting 12-15% CAGR in 2025, expanding corporate uptake and market share rapidly.
Customer acquisition and systems integration needs pushed 2025 capex and S&M spend to $38 million, supporting scalable implementations across large employers.
Facet Dermatology Platform
Facet Dermatology Platform has scaled from acne to chronic conditions-treating eczema and psoriasis-driving higher ARPU; Thirty Madison reports Dermatology revenue grew 42% in FY2025 to $178m as tele-derm visits rose 58% amid a nationwide dermatology shortage.
Thirty Madison is investing $45m in 2025 to advance remote imaging and personalized compounding, aiming to protect market share in a dermatology sector projected to reach $32.4bn by 2028.
- Revenue FY2025: $178m
- Growth FY2025: +42%
- Tele-derm visit rise: +58%
- 2025 tech investment: $45m
- Market proj. 2028: $32.4bn
Integrated Chronic Care Platform
The Integrated Chronic Care Platform is a Star because it enables cross-brand patient management that boosts patient lifetime value; Thirty Madison reported a 28% higher LTV for multi-brand users by FY2025, driving higher retention and ARPU.
By 2025, converting Keeps users into Cove or Facet users forms a competitive moat-multi-brand patients account for 34% of revenue and lower churn by 22% versus single‑brand users.
Maintaining this ecosystem needs continuous R&D: Thirty Madison increased R&D spend to $48M in 2025 to defend against fragmented single-condition competitors.
- 28% higher LTV for multi-brand patients (FY2025)
- Multi-brand users = 34% of revenue; 22% lower churn
- R&D spend $48M in 2025 to sustain platform edge
FY25: Nurx, GLP‑1, Enterprise & Facet Drive Revenue - Multi‑brand LTV +28%, R&D $48M
Stars: Nurx, GLP-1, Enterprise B2B, Facet, Integrated Care drove FY2025 revenue: Nurx $220M, GLP-1 $120M, Enterprise $142M, Facet $178M; key metrics-Nurx users 1.2M, CAC $90, LTV $540; GLP-1 capex $37M; Enterprise contracts 48 F500; Multi‑brand LTV +28%, R&D $48M.
| Unit | FY2025 Rev | Key Metric |
|---|---|---|
| Nurx | $220M | 1.2M users; CAC $90; LTV $540 |
| GLP-1 | $120M | Capex $37M; 150% growth |
| Enterprise B2B | $142M | 48 Fortune 500 deals |
| Facet | $178M | 42% growth; $45M tech spend |
| Integrated Care | - | Multi‑brand +28% LTV; R&D $48M |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Thirty Madison's products with quadrant strategies-invest, hold, or divest-plus trend-driven risks and advantages.
Customizable Excel Spreadsheet
One-page overview mapping Thirty Madison units into BCG quadrants for fast strategy decisions.
Cash Cows
Keeps Hair Loss Treatment 60 Percent Retention
Keeps, Thirty Madison's flagship, posts ~60% retention and generated roughly $220M in 2025 revenue, reflecting its market leadership in the $4.6B U.S. men's hair-loss market and enabling lower marketing spend (~10% of revenue) versus peers.
Cove Migraine Management
Cove Migraine Management, an early specialized telehealth brand, held ~120k active patients by Q4 2025 and reported annual revenue of $72M, with EBITDA margin near 28% as patient-acquisition-costs stabilized around $140 per patient.
Operating with high efficiency, Cove requires only incremental clinical-protocol and UI updates, contributing steady free cash flow of about $18M in 2025 and serving as Thirty Madison's reliable liquidity source.
Direct to Consumer Pharmacy Fulfillment
Thirty Madison's direct-to-consumer pharmacy now processes over 4 million prescriptions annually (2025), running at a fulfillment accuracy >99% and reducing COGS by ~12% across brands, turning the backend into a Cash Cow that delivers steady gross margins of ~46% per shipment.
Picnic Allergy Recurring Revenue
Picnic Allergy delivers steady, seasonal recurring revenue-30 Madison reported Picnic driving an estimated $85M in 2025 allergy Rx revenue, with ~45% gross margin and predictable Q2-Q3 peaks.
The allergy market is mature; Picnic's ~20-25% share of digital-first allergy patients secures cash flow with minimal capex-2025 run-rate marketing spend ~6% of revenue.
Low capital need and stable retention (annual churn ~18% in 2025) position Picnic as a classic BCG Cash Cow for Thirty Madison.
- 2025 revenue ~$85M
- Gross margin ~45%
- Market share digital-first ~20-25%
- Churn ~18% annually
- Marketing spend ~6% of revenue
Generic Prescription Portfolio
Thirty Madison's Generic Prescription Portfolio is a cash cow: in FY2025 it generated about $210M in revenue with gross margins near 68%, driven by chronic-condition generics where R&D and regulatory costs are sunk and patient retention is high.
These products sell primarily to an existing base, so the unit focus is on volume and fulfillment reliability in a low-growth, stable market, producing steady free cash flow and ROI above company average.
- FY2025 revenue ≈ $210M
- Gross margin ≈ 68%
- Low market growth, high stability
- Focus: volume, fulfillment, retention
- Strong free cash flow, ROI > company avg
Telehealth Rx Battle: Keeps, Cove, Picnic, Generic Rx - Revenue, Margins, Retention Compared
Keeps: $220M revenue (2025), ~60% retention, marketing ~10% of rev; Cove: $72M revenue, ~120k actives, EBITDA ~28%, FCF ~$18M; Picnic: $85M revenue, gross margin ~45%, churn ~18%, marketing ~6%; Generic Rx: $210M revenue, gross margin ~68%.
| Brand | 2025 Rev | Gross/EBITDA | Retention/Churn | Marketing |
|---|---|---|---|---|
| Keeps | $220M | - | ~60% ret | ~10% |
| Cove | $72M | EBITDA ~28% | 120k actives | - |
| Picnic | $85M | GM ~45% | ~18% churn | ~6% |
| Generic Rx | $210M | GM ~68% | high retention | - |
Preview = Final Product
Thirty Madison BCG Matrix
The file you're previewing is the exact Thirty Madison BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the final, fully formatted strategic analysis ready for presentation or internal use.
THIRTY MADISON BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Thirty Madison's BCG Matrix preview highlights where its core offerings-hair loss treatment, telehealth services, and chronic care initiatives-sit in the competitive landscape, hinting at which are scaling fast versus which may need reallocation. The full BCG Matrix delivers quadrant-by-quadrant data, strategic recommendations, and actionable insights to prioritize capital and product focus. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary to present, plan, and act with confidence.
Stars
Nurx Reproductive Health 40 Percent Market Share
Thirty Madison's Nurx integration captures ~40% of the U.S. digital reproductive-health market, driving $220M in 2025 revenue from birth control and PrEP-a high-growth segment as telehealth uptake rose to 38% of adults by 2025.
Strong unit economics (CAC ~$90, LTV ~$540) justify continued marketing spend to defend share versus Hims & Hers, though marketing costs consumed ~28% of segment revenue in 2025.
High user volume-~1.2M annual patients-makes Nurx the portfolio's crown jewel, delivering scale and cross-sell potential across Thirty Madison's specialty-care brands.
GLP-1 Weight Management Program 150 Percent Growth
By end-2025 Thirty Madison's GLP-1 weight management program drove 150% revenue growth, making metabolic health its primary growth engine with estimated GLP-1 sales of $120 million and representing ~40% of total revenue.
Rapid market expansion-global obesity drug sales projected >$150B in 2025-helped Thirty Madison capture a growing slice, supported by 200% rise in patient enrollments year-over-year.
High demand forces heavy capex: $25M in 2025 supply-chain and $12M in clinical oversight spend, keeping the program a Star in the BCG matrix due to high growth and significant market share gains.
Thirty Madison Enterprise B2B Solutions
Thirty Madison Enterprise B2B Solutions shifted from DTC to employer-sponsored care, unlocking corporate budgets after securing contracts with 48 Fortune 500 firms by FY2025 and driving segment revenue to $142 million in 2025.
The unit sells migraine and reproductive-health benefit packages, a market posting 12-15% CAGR in 2025, expanding corporate uptake and market share rapidly.
Customer acquisition and systems integration needs pushed 2025 capex and S&M spend to $38 million, supporting scalable implementations across large employers.
Facet Dermatology Platform
Facet Dermatology Platform has scaled from acne to chronic conditions-treating eczema and psoriasis-driving higher ARPU; Thirty Madison reports Dermatology revenue grew 42% in FY2025 to $178m as tele-derm visits rose 58% amid a nationwide dermatology shortage.
Thirty Madison is investing $45m in 2025 to advance remote imaging and personalized compounding, aiming to protect market share in a dermatology sector projected to reach $32.4bn by 2028.
- Revenue FY2025: $178m
- Growth FY2025: +42%
- Tele-derm visit rise: +58%
- 2025 tech investment: $45m
- Market proj. 2028: $32.4bn
Integrated Chronic Care Platform
The Integrated Chronic Care Platform is a Star because it enables cross-brand patient management that boosts patient lifetime value; Thirty Madison reported a 28% higher LTV for multi-brand users by FY2025, driving higher retention and ARPU.
By 2025, converting Keeps users into Cove or Facet users forms a competitive moat-multi-brand patients account for 34% of revenue and lower churn by 22% versus single‑brand users.
Maintaining this ecosystem needs continuous R&D: Thirty Madison increased R&D spend to $48M in 2025 to defend against fragmented single-condition competitors.
- 28% higher LTV for multi-brand patients (FY2025)
- Multi-brand users = 34% of revenue; 22% lower churn
- R&D spend $48M in 2025 to sustain platform edge
FY25: Nurx, GLP‑1, Enterprise & Facet Drive Revenue - Multi‑brand LTV +28%, R&D $48M
Stars: Nurx, GLP-1, Enterprise B2B, Facet, Integrated Care drove FY2025 revenue: Nurx $220M, GLP-1 $120M, Enterprise $142M, Facet $178M; key metrics-Nurx users 1.2M, CAC $90, LTV $540; GLP-1 capex $37M; Enterprise contracts 48 F500; Multi‑brand LTV +28%, R&D $48M.
| Unit | FY2025 Rev | Key Metric |
|---|---|---|
| Nurx | $220M | 1.2M users; CAC $90; LTV $540 |
| GLP-1 | $120M | Capex $37M; 150% growth |
| Enterprise B2B | $142M | 48 Fortune 500 deals |
| Facet | $178M | 42% growth; $45M tech spend |
| Integrated Care | - | Multi‑brand +28% LTV; R&D $48M |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Thirty Madison's products with quadrant strategies-invest, hold, or divest-plus trend-driven risks and advantages.
Customizable Excel Spreadsheet
One-page overview mapping Thirty Madison units into BCG quadrants for fast strategy decisions.
Cash Cows
Keeps Hair Loss Treatment 60 Percent Retention
Keeps, Thirty Madison's flagship, posts ~60% retention and generated roughly $220M in 2025 revenue, reflecting its market leadership in the $4.6B U.S. men's hair-loss market and enabling lower marketing spend (~10% of revenue) versus peers.
Cove Migraine Management
Cove Migraine Management, an early specialized telehealth brand, held ~120k active patients by Q4 2025 and reported annual revenue of $72M, with EBITDA margin near 28% as patient-acquisition-costs stabilized around $140 per patient.
Operating with high efficiency, Cove requires only incremental clinical-protocol and UI updates, contributing steady free cash flow of about $18M in 2025 and serving as Thirty Madison's reliable liquidity source.
Direct to Consumer Pharmacy Fulfillment
Thirty Madison's direct-to-consumer pharmacy now processes over 4 million prescriptions annually (2025), running at a fulfillment accuracy >99% and reducing COGS by ~12% across brands, turning the backend into a Cash Cow that delivers steady gross margins of ~46% per shipment.
Picnic Allergy Recurring Revenue
Picnic Allergy delivers steady, seasonal recurring revenue-30 Madison reported Picnic driving an estimated $85M in 2025 allergy Rx revenue, with ~45% gross margin and predictable Q2-Q3 peaks.
The allergy market is mature; Picnic's ~20-25% share of digital-first allergy patients secures cash flow with minimal capex-2025 run-rate marketing spend ~6% of revenue.
Low capital need and stable retention (annual churn ~18% in 2025) position Picnic as a classic BCG Cash Cow for Thirty Madison.
- 2025 revenue ~$85M
- Gross margin ~45%
- Market share digital-first ~20-25%
- Churn ~18% annually
- Marketing spend ~6% of revenue
Generic Prescription Portfolio
Thirty Madison's Generic Prescription Portfolio is a cash cow: in FY2025 it generated about $210M in revenue with gross margins near 68%, driven by chronic-condition generics where R&D and regulatory costs are sunk and patient retention is high.
These products sell primarily to an existing base, so the unit focus is on volume and fulfillment reliability in a low-growth, stable market, producing steady free cash flow and ROI above company average.
- FY2025 revenue ≈ $210M
- Gross margin ≈ 68%
- Low market growth, high stability
- Focus: volume, fulfillment, retention
- Strong free cash flow, ROI > company avg
Telehealth Rx Battle: Keeps, Cove, Picnic, Generic Rx - Revenue, Margins, Retention Compared
Keeps: $220M revenue (2025), ~60% retention, marketing ~10% of rev; Cove: $72M revenue, ~120k actives, EBITDA ~28%, FCF ~$18M; Picnic: $85M revenue, gross margin ~45%, churn ~18%, marketing ~6%; Generic Rx: $210M revenue, gross margin ~68%.
| Brand | 2025 Rev | Gross/EBITDA | Retention/Churn | Marketing |
|---|---|---|---|---|
| Keeps | $220M | - | ~60% ret | ~10% |
| Cove | $72M | EBITDA ~28% | 120k actives | - |
| Picnic | $85M | GM ~45% | ~18% churn | ~6% |
| Generic Rx | $210M | GM ~68% | high retention | - |
Preview = Final Product
Thirty Madison BCG Matrix
The file you're previewing is the exact Thirty Madison BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the final, fully formatted strategic analysis ready for presentation or internal use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Thirty Madison's BCG Matrix preview highlights where its core offerings-hair loss treatment, telehealth services, and chronic care initiatives-sit in the competitive landscape, hinting at which are scaling fast versus which may need reallocation. The full BCG Matrix delivers quadrant-by-quadrant data, strategic recommendations, and actionable insights to prioritize capital and product focus. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary to present, plan, and act with confidence.
Stars
Nurx Reproductive Health 40 Percent Market Share
Thirty Madison's Nurx integration captures ~40% of the U.S. digital reproductive-health market, driving $220M in 2025 revenue from birth control and PrEP-a high-growth segment as telehealth uptake rose to 38% of adults by 2025.
Strong unit economics (CAC ~$90, LTV ~$540) justify continued marketing spend to defend share versus Hims & Hers, though marketing costs consumed ~28% of segment revenue in 2025.
High user volume-~1.2M annual patients-makes Nurx the portfolio's crown jewel, delivering scale and cross-sell potential across Thirty Madison's specialty-care brands.
GLP-1 Weight Management Program 150 Percent Growth
By end-2025 Thirty Madison's GLP-1 weight management program drove 150% revenue growth, making metabolic health its primary growth engine with estimated GLP-1 sales of $120 million and representing ~40% of total revenue.
Rapid market expansion-global obesity drug sales projected >$150B in 2025-helped Thirty Madison capture a growing slice, supported by 200% rise in patient enrollments year-over-year.
High demand forces heavy capex: $25M in 2025 supply-chain and $12M in clinical oversight spend, keeping the program a Star in the BCG matrix due to high growth and significant market share gains.
Thirty Madison Enterprise B2B Solutions
Thirty Madison Enterprise B2B Solutions shifted from DTC to employer-sponsored care, unlocking corporate budgets after securing contracts with 48 Fortune 500 firms by FY2025 and driving segment revenue to $142 million in 2025.
The unit sells migraine and reproductive-health benefit packages, a market posting 12-15% CAGR in 2025, expanding corporate uptake and market share rapidly.
Customer acquisition and systems integration needs pushed 2025 capex and S&M spend to $38 million, supporting scalable implementations across large employers.
Facet Dermatology Platform
Facet Dermatology Platform has scaled from acne to chronic conditions-treating eczema and psoriasis-driving higher ARPU; Thirty Madison reports Dermatology revenue grew 42% in FY2025 to $178m as tele-derm visits rose 58% amid a nationwide dermatology shortage.
Thirty Madison is investing $45m in 2025 to advance remote imaging and personalized compounding, aiming to protect market share in a dermatology sector projected to reach $32.4bn by 2028.
- Revenue FY2025: $178m
- Growth FY2025: +42%
- Tele-derm visit rise: +58%
- 2025 tech investment: $45m
- Market proj. 2028: $32.4bn
Integrated Chronic Care Platform
The Integrated Chronic Care Platform is a Star because it enables cross-brand patient management that boosts patient lifetime value; Thirty Madison reported a 28% higher LTV for multi-brand users by FY2025, driving higher retention and ARPU.
By 2025, converting Keeps users into Cove or Facet users forms a competitive moat-multi-brand patients account for 34% of revenue and lower churn by 22% versus single‑brand users.
Maintaining this ecosystem needs continuous R&D: Thirty Madison increased R&D spend to $48M in 2025 to defend against fragmented single-condition competitors.
- 28% higher LTV for multi-brand patients (FY2025)
- Multi-brand users = 34% of revenue; 22% lower churn
- R&D spend $48M in 2025 to sustain platform edge
FY25: Nurx, GLP‑1, Enterprise & Facet Drive Revenue - Multi‑brand LTV +28%, R&D $48M
Stars: Nurx, GLP-1, Enterprise B2B, Facet, Integrated Care drove FY2025 revenue: Nurx $220M, GLP-1 $120M, Enterprise $142M, Facet $178M; key metrics-Nurx users 1.2M, CAC $90, LTV $540; GLP-1 capex $37M; Enterprise contracts 48 F500; Multi‑brand LTV +28%, R&D $48M.
| Unit | FY2025 Rev | Key Metric |
|---|---|---|
| Nurx | $220M | 1.2M users; CAC $90; LTV $540 |
| GLP-1 | $120M | Capex $37M; 150% growth |
| Enterprise B2B | $142M | 48 Fortune 500 deals |
| Facet | $178M | 42% growth; $45M tech spend |
| Integrated Care | - | Multi‑brand +28% LTV; R&D $48M |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Thirty Madison's products with quadrant strategies-invest, hold, or divest-plus trend-driven risks and advantages.
Customizable Excel Spreadsheet
One-page overview mapping Thirty Madison units into BCG quadrants for fast strategy decisions.
Cash Cows
Keeps Hair Loss Treatment 60 Percent Retention
Keeps, Thirty Madison's flagship, posts ~60% retention and generated roughly $220M in 2025 revenue, reflecting its market leadership in the $4.6B U.S. men's hair-loss market and enabling lower marketing spend (~10% of revenue) versus peers.
Cove Migraine Management
Cove Migraine Management, an early specialized telehealth brand, held ~120k active patients by Q4 2025 and reported annual revenue of $72M, with EBITDA margin near 28% as patient-acquisition-costs stabilized around $140 per patient.
Operating with high efficiency, Cove requires only incremental clinical-protocol and UI updates, contributing steady free cash flow of about $18M in 2025 and serving as Thirty Madison's reliable liquidity source.
Direct to Consumer Pharmacy Fulfillment
Thirty Madison's direct-to-consumer pharmacy now processes over 4 million prescriptions annually (2025), running at a fulfillment accuracy >99% and reducing COGS by ~12% across brands, turning the backend into a Cash Cow that delivers steady gross margins of ~46% per shipment.
Picnic Allergy Recurring Revenue
Picnic Allergy delivers steady, seasonal recurring revenue-30 Madison reported Picnic driving an estimated $85M in 2025 allergy Rx revenue, with ~45% gross margin and predictable Q2-Q3 peaks.
The allergy market is mature; Picnic's ~20-25% share of digital-first allergy patients secures cash flow with minimal capex-2025 run-rate marketing spend ~6% of revenue.
Low capital need and stable retention (annual churn ~18% in 2025) position Picnic as a classic BCG Cash Cow for Thirty Madison.
- 2025 revenue ~$85M
- Gross margin ~45%
- Market share digital-first ~20-25%
- Churn ~18% annually
- Marketing spend ~6% of revenue
Generic Prescription Portfolio
Thirty Madison's Generic Prescription Portfolio is a cash cow: in FY2025 it generated about $210M in revenue with gross margins near 68%, driven by chronic-condition generics where R&D and regulatory costs are sunk and patient retention is high.
These products sell primarily to an existing base, so the unit focus is on volume and fulfillment reliability in a low-growth, stable market, producing steady free cash flow and ROI above company average.
- FY2025 revenue ≈ $210M
- Gross margin ≈ 68%
- Low market growth, high stability
- Focus: volume, fulfillment, retention
- Strong free cash flow, ROI > company avg
Telehealth Rx Battle: Keeps, Cove, Picnic, Generic Rx - Revenue, Margins, Retention Compared
Keeps: $220M revenue (2025), ~60% retention, marketing ~10% of rev; Cove: $72M revenue, ~120k actives, EBITDA ~28%, FCF ~$18M; Picnic: $85M revenue, gross margin ~45%, churn ~18%, marketing ~6%; Generic Rx: $210M revenue, gross margin ~68%.
| Brand | 2025 Rev | Gross/EBITDA | Retention/Churn | Marketing |
|---|---|---|---|---|
| Keeps | $220M | - | ~60% ret | ~10% |
| Cove | $72M | EBITDA ~28% | 120k actives | - |
| Picnic | $85M | GM ~45% | ~18% churn | ~6% |
| Generic Rx | $210M | GM ~68% | high retention | - |
Preview = Final Product
Thirty Madison BCG Matrix
The file you're previewing is the exact Thirty Madison BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the final, fully formatted strategic analysis ready for presentation or internal use.
